Researchers at Albert Einstein College of Medicine in the Bronx, NY past year said they believe the condition starts in utero and that it is a developmental disorder.
The study was made possible with funding and operational support from Brain Canada, the Canadian Institutes for Health Research, CANARIE, Compute Canada, the Canadian Foundation for Innovation and the Molson Postdoctoral Neuro-Engineering Fellowship of McGill University. And VR has been used to predict the early onset of the disease.
A large part of the challenge in creating an early Alzheimer's test is being able to consistently find the abnormally formed brain proteins that signal the disease's emergence and likely cause its symptoms, amyloid beta and tau.
There are some 7.5 million new cases of Alzheimer's - a degenerative disease that causes serious problems with memory, thinking ability and behavior - diagnosed around the world.
The research team, which is comprised of scientists from the Institute of Molecular Medicine, University of California and Flinders University, are now collaborating with experts from four pharmaceutical companies to conduct non-clinical safety-toxicology studies in order to fill United States safety standards. "Second, since there are no available early detection techniques, drugs now can not be tested to determine if they are effective against early Alzheimer's disease". "We saw changes in the retinas of Alzheimer's mice before the typical age at which neurological signs are observed", said More.
Indeed, researchers detected patterns in the retinas - through changes in light reflection as early stages of amyloid plaque gathered - that signified the disease's progression. The eye test will enter human trials this month, and it will be tested in both patients with and without Alzheimer's disease.
Administering the primary female sex hormone oestrogen via a skin patch shortly after menopause may reduce Alzheimer's risk in women, suggests new research.
Alzheimer's Society research officer Ian Le Guillou said: "These interesting findings suggest that people with the APOE4 gene - which increases the risk of developing Alzheimer's disease - have differences in their brains from childhood".
The rapid estrogen decline following menopause usually happens 12 months after the woman's last menstrual period.
Women with APOE e4, a form of the most common gene associated with the Alzheimer's disease also had lower levels of neuron harming amyloid deposits. "It also may have a significant impact on women making the decision to use hormone therapy in the early postmenopausal years".